- Home
- MQ vs SUPN Comparison
MQ vs SUPN Comparison
Compare MQ & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQ
- SUPN
- Stock Information
- Founded
- MQ 2010
- SUPN 2005
- Country
- MQ United States
- SUPN United States
- Employees
- MQ N/A
- SUPN N/A
- Industry
- MQ Computer Software: Prepackaged Software
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- MQ Technology
- SUPN Health Care
- Exchange
- MQ Nasdaq
- SUPN Nasdaq
- Market Cap
- MQ 1.9B
- SUPN 2.1B
- IPO Year
- MQ 2021
- SUPN 2012
- Fundamental
- Price
- MQ $3.70
- SUPN $38.58
- Analyst Decision
- MQ Buy
- SUPN Hold
- Analyst Count
- MQ 16
- SUPN 1
- Target Price
- MQ $5.62
- SUPN $36.00
- AVG Volume (30 Days)
- MQ 3.8M
- SUPN 361.3K
- Earning Date
- MQ 02-26-2025
- SUPN 02-25-2025
- Dividend Yield
- MQ N/A
- SUPN N/A
- EPS Growth
- MQ N/A
- SUPN 130.79
- EPS
- MQ 0.03
- SUPN 1.07
- Revenue
- MQ $490,027,000.00
- SUPN $651,972,000.00
- Revenue This Year
- MQ N/A
- SUPN $7.77
- Revenue Next Year
- MQ $15.65
- SUPN N/A
- P/E Ratio
- MQ $137.79
- SUPN $36.07
- Revenue Growth
- MQ N/A
- SUPN 6.79
- 52 Week Low
- MQ $3.37
- SUPN $25.53
- 52 Week High
- MQ $7.36
- SUPN $39.37
- Technical
- Relative Strength Index (RSI)
- MQ 42.50
- SUPN 63.92
- Support Level
- MQ $3.54
- SUPN $37.27
- Resistance Level
- MQ $3.93
- SUPN $38.68
- Average True Range (ATR)
- MQ 0.15
- SUPN 1.01
- MACD
- MQ 0.01
- SUPN 0.12
- Stochastic Oscillator
- MQ 35.56
- SUPN 96.61
About MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.